Philip A. Pancari, MD
Medical Oncology, Hematology
Languages: English
Residency
Thomas Jefferson University Hospital, Philadelphia, PA
Thomas Jefferson University Hospital, Philadelphia, PA
Education:
Boston University School of Medicine, Boston, MA
Boston University School of Medicine, Boston, MA
Member
American Society of Hematology, American Society of Clinical Oncology, American Society for Blood and Marrow Transplantation, National Comprehensive Cancer Network (panel member)
American Society of Hematology, American Society of Clinical Oncology, American Society for Blood and Marrow Transplantation, National Comprehensive Cancer Network (panel member)
Fellowship
Hematology and Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA
Hematology and Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA
Leadership
Served on multiple NCCN panels for the generation of national diagnostic and treatment guidelines, specifically for myeloproliferative disease, chronic myeloid leukemia (CML), acute lymphoblastic leukemia (B-ALL), and systemic mastocytosis. Acted as principal investigator for multiple prospective clinical trials, including studies of novel immunotherapeutic approaches.
Served on multiple NCCN panels for the generation of national diagnostic and treatment guidelines, specifically for myeloproliferative disease, chronic myeloid leukemia (CML), acute lymphoblastic leukemia (B-ALL), and systemic mastocytosis. Acted as principal investigator for multiple prospective clinical trials, including studies of novel immunotherapeutic approaches.
“A cancer diagnosis is like no other in that it can alter a life so abruptly and thoroughly. I have found that no person’s cancer is strictly the same as anyone else’s, even if it’s the same type of cancer. So, I must analyze and treat my patient’s cancer in a purely unique manner — one that isn’t overly influenced by patterns, routines or averages.
As an oncologist, I’ve been given the opportunity to work with people throughout the most challenging chapter of their lives, and I have the benefit of offering them an ever-increasing array of advanced therapeutic approaches. Treatments such as targeted oral options and immunotherapies acknowledge that cancer diagnoses are as distinct as the patients themselves. I aspire to personally guide each patient not only to his or her best possible clinical outcome, but also to bring comfort, confidence and empowerment into the journey.”